Clinical Trials Logo
  1. Home
  2. Benign Prostatic Hyperplasia
  3. NCT05784558
  4. Details
NCT05784558 Clinical Trial

RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up

Benign Prostatic Hyperplasia Clinical Trial

— RELIEF  

Official title:
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05784558
Other study ID # CP00022
Secondary ID CP00022
Status Not yet recruiting
Phase
First received
Last updated
Start date April 3, 2023
Est. completion date December 31, 2030

Study information
Verified date February 2023
Source NeoTract, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of the RELIEF Study is to compare the safety, effectiveness and patient experience outcomes in real-world subjects treated with different modalities for symptomatic BPH.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 2500
Est. completion date December 31, 2030
Est. primary completion date December 31, 2029
Accepts healthy volunteers No
Gender Male
Age group 45 Years and older
Eligibility Inclusion Criteria: - Diagnosis of symptomatic BPH Exclusion Criteria: - Prior surgical intervention for treatment of BPH - Unable or unwilling to give informed consent or unwilling to complete all required questionnaires and follow-up assessments

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• UroLift System
The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
Other:
• Watchful Waiting or BPH Medications
Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
Device:
• Other Surgical Intervention
Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
NeoTract, Inc.

Outcome
Type Measure Description Time frame Safety issue
Primary To identify responders of IPSS change Change of >3 points in IPSS score from baseline to the 3 months post-treatment visit. 3 months post-treatment visit
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A